DIDiana A. Ivanova

Diana A. Ivanova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Diana A. Ivanova has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A new look at the alimentary route of tuberculosis transmission using a rabbit model (experimental study)

    by M. N. Reshetnikov, D. V. Plotkin, T. I. Vinogradova, M. Z. Dogonadze, D. A. Ivanova, O. N. Zuban, P. K. Yablonsky

    Background . The increase in the number of cases of generalized tuberculosis infection with intestinal damage, especially in HIV-positive patients, underscores the need for further study of this problem. Tuberculosis is transmitted by airborne droplets; however, there are known cases of intestinal tuberculosis in which infection occurred through the alimentary route. Since such cases are extremely rare, there are likely specific immunological and epidemiological conditions that allow Mycobacterium tuberculosis to penetrate the intestinal wall and develop primary inflammation. The aim . To study the possibility of an alimentary route of tuberculosis infection in immunocompetent and immunocompromised individuals using a reproducible rabbit model. Materials and Methods . The experiment involved rabbits, divided into three groups. Animals were orally administered a suspension of a standard laboratory isolate Mycobacterium tuberculosis H37Rv. The first group included immunocompetent rabbits immunosuppressed with infliximab, the second group had animals reinfected against the background of immunodeficiency, and the third group included rabbits with a combination of drug-induced immunosuppression and chemically induced enterocolitis. To assess the results of infection, clinical observation, detection of MTB DNA in feces, skin test with ATR, pathoanatomical, histological and molecular genetic examination of organs were used. Results . Despite the temporary shedding of MTB DNA in feces (60–70 %), no signs of tuberculous inflammation in the organs were present in animals in groups 1 and 2. In group 3, macroand microscopic signs of tuberculosis were detected in the lungs of 83.3 % of the animals and in the mesenteric/intrathoracic lymph nodes of 58.3 %. At the same time, no specific granulomatous intestinal lesions were found in any of the groups. Conclusion . The development of tuberculous enterocolitis in rabbits following oral infection is unlikely. The alimentary route of infection can lead to generalized tuberculosis only when two key predisposing factors are present: systemic immunosuppression and previous damage to the intestinal barrier.

  • Open Access

    Therapeutic drug monitoring in the treatment of patients with drug-resistant tuberculosis

    by Diana A. Ivanova, Иванова Диана Александровна, Ekaterina I. Yurovskaya, Юровская Екатерина Игоревна, Ksenia Yu. Galkina, Галкина Ксения Юрьевна, Mikhail N. Reshetnikov, Решетников Михаил Николаевич, Dmitrii V. Plotkin, Плоткин Дмитрий Владимирович, et al.

    Aim. Testing of therapeutic drug monitoring in the treatment of drug-resistant tuberculosis. Materials and methods. We conducted a pilot prospective study including 15 patients with drug-resistant tuberculosis. Serum concentrations of bedaquiline, linezolid, fluoroquinolone, cycloserine, delamanid (C2h) were determined by high-performance liquid chromatography and mass spectrometry. The influence of clinical and pharmacogenetic factors were evaluated. Results. In most patients, C2h of the drugs were subtherapeutic (57.1% for bedaquiline, 73.3% for linezolid). C2h of bedaquiline were higher in patients with homozygous rs776746 in the CYP3A5 gene (p=0.04), in case of simultaneous omeprazole (p=0.015), high drug load (p=0.005); linezolid – in patients with rs776746 in the CYP3A5 gene (p=0.038) and rs34351236 in the P-glycoprotein gene (p=0.014). The course of chemotherapy was effective in 14 of 15 patients. A factor for cavity closure was a C2h/critical concentration ratio above 1.0 for fluoroquinolone (odds ratio 3.5, 95% confidence interval 1.08–11.24). Conclusion. Therapeutic drug monitoring is a perspective tool for personalized approach to improve treatment outcomes in high-risk drug-resistant tuberculosis patients.

  • Efficacy of surgical intervention in modern complex treatment for tuberculosis with multidrug-resistant and extensively drug-resistant pathogen

    by S. A. Kosenkov, D. A. Ivanova, M. V. Sinitsyn

    Background . One of the top priorities in phthisiology at present is the problem of tuberculosis treatment with multiple drug resistance (MDR) and extensive drug resistance (XDR) Mycobacterium tuberculosis (MBT). The unsatisfactory results of etiotropic chemotherapy associated with a large number of factors determine the need for surgical treatment. The effectiveness of surgical treatment and the advantages of using surgical techniques (in combination with chemotherapy) compared to the use of chemotherapy alone, it is currently poorly understood and undoubtedly requires research at various levels. The aim . Evaluation of the effectiveness and determination of optimal timing and risks of surgical intervention in the framework of complex treatment of tuberculosis with MDR/XDR pathogen using modern chemotherapy regimens. Materials and methods . The data on the treatment outcomes of 71 patients with MDR/XDR pathogen after surgery who received identical modern chemotherapy regimens (including bedaquiline, linezolid, fluoroquinolones, cycloserine) with a catamnesis of sufficient duration (at least 5 years) were analyzed. Results . Successful treatment outcome (cure with transfer to the III GDN or de-registration) was registered in 83.1 % (95% CI 72.6-90.2 %). One independent risk factor for an unfavorable outcome was identified - the presence of behavioral characteristics of the patient, indicating his low adherence to treatment (p = 0.014). For relapse, the only independent risk factor was taking less than 90 doses of drugs according to the treatment regimen for drug-resistant tuberculosis, including bedaquiline and linezolid before surgery (p = 0.013). Conclusion . The high efficiency of complex treatment during surgical intervention against the background of MDR/XDR-tuberculosis chemotherapy regimens with the inclusion of bedaquiline and linezolid has been shown. The priority role of working with patients' commitment to treatment for the prevention of adverse outcomes has been confirmed. The optimal duration of preoperative chemotherapy according to the “new” regimens (3 months or more) has been determined.

  • Open Access

    Efficacy and safety of delamanid -containing regimens of anti-tuberculosis chemotherapy in real clinical practice: a cohort study

    by S. A. Zhirkova, D. A. Ivanova, N. V. Litvinova

    The spread of multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB) is stimulating the search for new drugs and chemotherapy regimens. Delamanid (Dlm) has been used in Russia since 2021; its efficacy and safety as part of chemotherapy regimens, advantages and limitations in Russian clinical practice have not been fully studied. The aim was a comparative analysis of the efficacy and safety of DR-TB chemotherapy regimens with and without Dlm in real clinical practice. Method. The observational study included 200 HIV-uninfected adult patients with pulmonary drug-resistant TB; 100 рatients of prospective cohort received Dlm-containing chemotherapy regimens (since 2021), and 100 patients of retrospective cohort – similar regimens without Dlm (in 2016–2020). The effectiveness of treatment was analyzed in those who completed the course («per protocol»), and among all who started treatment («intention-to-treat»). Results. The effectiveness of treatment per protocol in patients completed the 24-week course was 94.1% vs. 87% (p > 0.05), in those who completed the main course of treatment – 91.0% vs. 80.5% in prospective and retrospective cohorts, respectively (p = 0.06). In the ITT analysis, a bacteriological response was noted in 93.2% vs. 87.7%; mortality was 3% and 5% in the group with and without Dlm, respectively (p > 0.05). In patients with a disease duration of up to 12 months, the time to sputum conversion was shorter for Dlm-containing regimens (median 4 wks vs 8 wks, p = 0.002). There were no differences in the frequency of significant adverse reactions (grades 3–4, 26% vs. 25%, respectively, p > 0.05); neurotoxic reaction (36% vs. 21%, p < 0.05), QT prolongation and gastrointestinal reactions were more frequent in the prospective cohort. Conclusion. The inclusion of delamanid in modern chemotherapy regimens for MDR-TB helps to increase the effectiveness of treatment, especially in patients with disease duration up to a year; prevention and monitoring of neurotoxic reactions are necessary.

  • Open Access

    Antiviral therapy for hepatitis C in patients with tuberculosis

    by D. A. Ivanova, E. Yu. Romanova, Yu. Yu. Mitrofanova, A. S. Galstyan, O. V. Rodina, Ю. Ю. Митрофанова

    The aim. The study was to evaluate the effectiveness and safety of co-administration of antituberculosis and antiviral therapy (AVT) in patients with coinfection of chronic viral hepatitis C and pulmonary tuberculosis. Materials and methods. The observational study included 52 patients with active tuberculosis (63.5% drug-resistant cases) and chronic viral hepatitis C; 11 of them received a course of antiviral therapy (pan-genotypic regimens), 8 patients – simultaneously with anti-tuberculosis treatment (ATT, regimens without rifampicin), another 3 – before the start of tuberculosis treatment. Results. All 8 patients (100%) who received simultaneous AVT and ATT demonstrated a virological response; 7 days after the start of AVT, a complete normalization of transaminase levels was observed, which made it possible to prescribe an adequate ATT regimen and achieve successful treatment of tuberculosis. Two patients experienced mild adverse reactions, including transient eosinophilia, associated with the use of anti-tuberculosis drugs. After AVT, liver enzyme levels remained normal until completion of anti-tuberculosis treatment; in group without AVT (n = 41), the incidence of drug-induced liver injury was 61.0% (p < 0.001). Conclusion. Co-administration of anti-tuberculosis and antiviral therapy in tuberculosis patients with chronic hepatitis C is safe and effective. Pangenotypic AVT regimens are optimal. It is better to start including anti-tuberculosis drugs from the second week of antiviral treatment.

  • Open Access

    Nutritional deficiency in patients with tuberculosis

    by M. V. Tityukhina, D. A. Ivanova, A. S. Konovalov, N. V. Litvinova, G. N. Kholmogorova

    Undernutrition is one of the key risk factors for tuberculosis, complicating the course and treatment of the disease in almost every second patient, and significantly affecting the prognosis. The review examines current concepts of the classification, causes, and pathogenesis of undernutrition in tuberculosis patients, including the role of drug-induced nutritional deficiency. The main methods for identifying nutritional deficiencies and validated scales for assessing nutritional risk in tuberculosis patients are described. The article examines the basic principles and practical issues of implementing nutritional support as the main method for correcting undernutrition in patients with tuberculosis.

  • Open Access

    Potential of Pharmacogenetic Testing in Tuberculosis Treatment

    by D. A. Ivanova, N. Yu. Nikolenko, K. Yu. Galkina, E. I. Yurovskaya, Yu. Yu. Mitrofanova, D. A. Kudlay, Ю. Ю. Митрофанова

    Pharmacogenetic testing is the most promising tool in personalized medicine aimed at enhancing effectiveness and safety of treatment, especially in complicated cases with comorbidities. The review analyzes 122 publications devoted to theoretical and applied aspects of pharmacogenetic testing in the treatment of tuberculosis patients. It considers the role of genetic polymorphisms in the response to treatment, and presents data on proteins involved in pharmacokinetics and pharmacodynamics of main anti-tuberculosis drugs and the genes encoding these proteins. The review analyzes the list of the most significant markers associated with the risk of adverse reactions during treatment of drug-sensitive and drug-resistant tuberculosis, and it characterizes prospects for their use in clinical practice. The list of references contains 56 key publications cited in the text.

  • Open Access

    Pharmacogenetic markers in the treatment of patients with multidrug-resistant tuberculosis.

    by D. A. Ivanova, E. I. Yurovskaya, K. Yu. Galkina

    Relevance . The treatment of patients with multidrug-resistant tuberculosis (MDR-TB) is often complicated by adverse drug reactions (ADRs) necessitating drug discontinuation. Its effectiveness falls short of target indicators and depends on a number of factors, including the patient's genetic profile. Pharmacogenetic markers for MDR-TB remain unstudied; their identification is expected to improve treatment outcomes through a personalized approach. Objective . To determine pharmacogenetic markers associated with the efficacy and safety of treatment in patients with multidrug-resistant tuberculosis. Materials and methods . A prospective cohort study included 40 patients with MDR-TB without HIV infection, receiving therapy with regimens containing bedaquiline, linezolid, and a fluoroquinolone in 2023-2024. A single 3-5 ml venous blood sample was collected from all patients irrespective of treatment duration. The presence of single nucleotide polymorphisms (SNPs) in cytochrome genes (CYP3A4, CYP3A5), P-glycoprotein (ABCB1), ATP-binding cassette transporter (ABCG2), and organic anion transporter (SLCO1B1) was determined using real-time PCR. These genes were selected based on literature and PharmGKB database analysis. Their association with treatment efficacy and safety parameters was assessed using univariate analysis, calculating odds ratios (OR) and 95% confidence intervals (95% CI). Results. The following target polymorphisms were identified: SLCO1B1 (rs4149056, in 25.8%), ABCB1 (rs1045642 — in 75.0 %, rs2032582 — 72.2 %, rs1128503 — 77.8 %), ABCG2 (rs2231142 — in 24.3 %), CYP3A4 (rs2740574 — in 8.1 %), CYP3A5 (rs776746 — in 10.8 %). Treatment efficacy based on the criterion of sputum culture conversion was 89.3% (95% CI 72.0-97.1 %); the incidence of ADRs was 70 % (95 % CI 54.5-82.0 %), with neurotoxic reactions predominating (in 11 of 40 patients, 27.5 %). The CYP3A5 rs776746 AA genotype and the ABCG2 rs2231142 AA genotype were associated with the lowest rates of sputum culture conversion: 33 % and 0 % of individuals with each variant, respectively, compared to 100% in others, p < 0.01, OR 0.021 (95 % CI 0.001-0.77) and 0.083 (95 % CI 0.01-0.98). The risk of neurotoxic reactions was higher in the presence of the wild-type GG genotype of the ABCB1 rs2032582 gene (55.6 % vs. 16.0 % in patients with allelic polymorphisms, p = 0.034, OR 6.3, 95 % CI 1.2-33.3); the risk of gastrointestinal reactions was higher with the TT genotype of the ABCB1 rs1128503 gene (50.0 % vs. 10.0%, p = 0.045, OR = 9.0, 95 % CI 1.22-66.2). Conclusion . Polymorphisms in the CYP3A5 (rs776746, genotype AA) and ABCG2 (rs2231142, genotype AA) genes associated with unfavorable treatment outcomes in MDR-TB patients were identified. Genetic predictors of neurotoxic and gastrointestinal reactions during the treatment of patients with multidrugresistant pathogen were determined.


  • Open Access

    Pharmacogenetic markers in the treatment of patients with multidrug-resistant tuberculosis

    by D. A. Ivanova, E. I. Yurovskaya, K. Yu. Galkina

    Background . Treatment of patients with tuberculosis (TB) with multidrug-resistant (MDR) causative agent is often complicated by adverse reactions (AR) with forced drug discontinuation, its effectiveness is far from the target indicators and depends on a number of factors, including the patient's genetic characteristics. Pharmacogenetic markers of MDR-TB have not been studied; it is expected that their identification will improve the results of treatment based on a personalized approach. Objective. to determine the pharmacogenetic markers associated with the efficacy and safety of treatment of patients with MDR TB. Methods. A prospective cohort study included 40 patients with MDR-TB without HIV infection who received therapy with bedaquiline, linezolid, and a fluoroquinolone in 2023–2024. All patients had 3–5 ml of venous blood collected once, regardless of the duration of therapy. Real-time PCR was used to determine the presence of single-nucleotide polymorphisms in the genes for cytochromes (CYP3A4, CYP3A5), P-glycoprotein (ABCB1), the membranebound ATP-binding cassette transporter (ABCG2), and the organic anion transporter (SLCO1B1), which were selected based on literature analysis and the PharmGKB database. The relationship between these indicators and the effectiveness and safety of treatment was assessed using univariate analysis, with the calculation of the odds ratio (OR) and its 95 % confidence interval (CI). The results . Target polymorphisms were identified: SLCO1B1 (rs4149056 — in 25.8 %), ABCB1 (rs1045642 — in 75.0 %, rs2032582 — 72.2 %, rs1128503 — 77.8 %), ABCG2 (rs2231142 — in 24.3 %), CYP3A4 (rs2740574 — in 8.1 %), CYP3A5 (rs776746 — in 10.8 %). The treatment efficacy based on the criterion of cessation of bacteriosis was 89.3 % (95 % CI 72.0–97.1 %); the incidence of adverse events was 70 % (95 % CI 54.5–82.0 %), with neurotoxic reactions prevailing (in 11 of 40 patients, 27.5 %). The AA genotypes of the CYP3A5 rs776746 gene and the AA genotypes of the ABCG2 rs2231142 gene were associated with a minimum frequency of cessation of bacterial shedding: respectively, in 33 % and 0% of individuals with each variant, compared to 100% in the rest, p < 0.01; OR 0.021 (95 % CI 0.001–0.77) and 0.083 (95% CI 0.01–0.98). The risk of neurotoxic reactions was higher in the presence of the "wild" variant (genotype GG) of the ABCB1 rs2032582 gene (55.6 % vs. 16.0 % in patients with allelic polymorphisms, p = 0.034; OR 6.3; 95 % CI 1.2–33.3); gastrointestinal reactions — in the presence of the TT genotype of the ABCB1 rs1128503 gene (50.0 % vs. 10.0 %, p = 0.045; OR=9.0; 95 % CI 1.22–66.2 %). Conclusion . Polymorphisms of CYP3A5 (rs776746, AA genotype) and ABCG2 (rs2231142, AA genotype) genes were revealed, associated with unfavorable results of treatment of patients with MDR-TB. Genetic predictors of neurotoxic and gastrointestinal reactions during treatment of patients with MDR of the pathogen were determined.


  • Open Access

    The effect of surgical treatment jn long-term treatment outcomes in patients with pulmonary tuberculosis

    by S. A. Kosenkov, D. A. Ivanova, M. V. Sinitsyn, A. A. Vorobyev

    The aim of the study was to evaluate the influence of surgical treatment on the long-term results of complex treatment of patients with pulmonary tuberculoma.Materials and methods. The retrospective cohort study analyzed the long-term outcomes of treatment in patients with pulmonary tuberculoma: without surgical treatment – 25 patients, and those who underwent surgical intervention during the study period (2017–2018) – 50 patients. The method of pair matching (2:1) was used to form the groups. The target variable was the frequency and structure of unfavorable treatment outcomes registered within 5 years from the beginning of treatmentResults. Successful treatment outcome (clinical cure, deregistration due to recovery) at the end of the five-year follow-up period was recorded in 49 of 50 patients after surgical treatment (98.0%, 95% CI 88.5–100%) and in 19 of 25 patients in the control cohort (without surgical treatment) (76.0%, 95% CI 56.3–88.8%), p = 0.008 by χ2 test. When only TB-related adverse outcomes (without mortality from other causes) were considered, the group differences remained significant: 16.0% (95%CI 5.8–35.3%) and 0% adverse outcomes in the cohorts with and without surgical treatment, respectively, p = 0.004 by χ2.Conclusion. Surgical treatment for tuberculomas significantly reduced the likelihood of an adverse outcome by 11.8 times (OR = 0.07, 95%CI 0.007–0.614) and improved the prognosis of patients within 5 years of registration for treatment.